A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
30/09/2021at 14:29

Roche dismisses Novo Nordisk as potential threat on lucrative hemophilia market

Novo Nordisk's future hemophilia drugs face a difficult challenge in reconquering the profitable hemophilia drug market, says CEO at Roche, which is currently shepherding a big part of the loyal hemophiliac flock.
Photo: Roche / PR
Finans
BY Leonora beck, TRANSLATED BY DANIEL PEDERSEN

The pharmaceutical giant Roche has in a short time seized large portions of the world's hemophiliac market, a lead that the Swiss company and competitor of Novo Nordisk expects to maintain.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Roche: The US and Asia outsprint Europe in life science sector

    For subscribers

  • Photo: Novo Nordisk / PR

    Novo Nordisk prepares phase III trial of potential blockbuster drug

    For subscribers

  • Photo: Michael Buholzer/Reuters/Ritzau Scanpix

    Roche's hemophilia treatment well on the way to triple blockbuster status

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup
Pharma & biotech

Potential blockbuster submitted by Novo Nordisk for European approval

The EMA can begin reviewing hemophilia treatment concizumab, which used to carry the orphan drug badge until recently, when the company decided not to take advantage of the status.
  • Novo Nordisk renounces orphan drug title for potential blockbuster
  • Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Photo: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

For subscribers

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Photo: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Photo: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Photo: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Further reading

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Foto: Novo Nordisk / PR
Pharma & biotech

Novo Nordisk wins case in US appeals court

Three pharmaceutical firms, including Novo Nordisk, have won a case in a US appeals court, which agreed that the drugmakers can limit deliveries of federally discounted drugs.

For subscribers

Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Photo: Anne Bæk/Ritzau Scanpix
Pharma & biotech

Orphazyme trio founds new firm focused on neurology and rare diseases

Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.

For subscribers

Latest news

  • Potential blockbuster submitted by Novo Nordisk for European approval – 13:51
  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, sets new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
See all

Jobs

  • Application Manager

  • Clinical Operational Associate

  • Commercial Director

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Regulatory Affairs Professional

  • Senior Regulatory Affairs Professional

See all jobs

Jobs

  • Application Manager

  • Clinical Operational Associate

  • Commercial Director

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Regulatory Affairs Professional

  • Senior Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge